Table 2.
Progress, complications, and outcomes.
| COVID-19 ECMO patients (n = 24) | COVID-19 non ECMO patients (n = 62) | p value | Matched cohorts (n = 24) | p-value | |
|---|---|---|---|---|---|
| LOS ICU (days) | 33.21 ± 23.16 | 17.70 ± 17.56 | <0.001 | 30.82 ± 21.48 | 0.78 |
| LOS total (days) | 38.35 ± 25.88 | 25.43 ± 20.31 | <0.01 | 40.86 ± 24.25 | 0.74 |
| ICU mortality | 11 (45.80%) | 4 (6.50%) | <0.001 | 4 (16.6%) | 0.02 |
| 3-month mortality | 12 (50.00%) | 4 (6.50%) | <0.001 | 4 (16.6%) | <0.001 |
| Highest SOFA score | 12.17 ± 2.46 | 6.59 ± 4.61 | <0.001 | 11.95 ± 4.25 | 0.54 |
| PaO2 | 62.27 ± 13.38 | 57.02 ± 12.57 | 0.12 | 53.96 ± 11.45 | 0.03 |
| PaCO2 | 49.55 ± 13.16 | 38.52 ± 11.79 | <0.001 | 42.17 ± 11.98 | 0.04 |
| pH | 7.32 ± 0.09 | 7.31 ± 0.89 | <0.001 | 7.39 ± 0.19 | 0.04 |
| SaO2 | 89.05 ± 4.56 | 87.79 ± 5.19 | 0.47 | 86.08 ± 5.36 | 0.08 |
| Lactate | 2.05 ± 2.56 | 1.55 ± 0.54 | 0.77 | 1.58 ± 0.65 | 0.38 |
| P/F ratio | 64.59 ± 14.22 | 72.27 ± 47.26 | 0.29 | 59.17 ± 17.82 | 0.04 |
| Invasive mechanical ventilation | 24 (100%) | 30 (48.39%) | <0.001 | 24 (100%) | 1.00 |
| Prone ventilation | 24 (100%) | 45 (72.60%) | <0.01 | 21 (87.50%) | 0.07 |
| PEEP | 11.05 ± 2.20 | 14.48 ± 3.82 | 0.03 | 13.52 ± 3.86 | 0.01 |
| PIP | 24.74 ± 4.86 | 34.48 ± 7.82 | <0.001 | 33.42 ± 8.52 | <0.01 |
| Neuromuscular blockers | 20 (83.33%) | 27 (43.55%) | <0.001 | 21 (87.50%) | 0.24 |
|
| |||||
| Treatment | |||||
| Corticosteroid | 22 (91.7%) | 53 (85.5%) | 0.44 | 20 (83.3%) | 0.38 |
| Plaquenil | 2 (8.3%) | 13 (21.0%) | 0.16 | 8 (33.3%) | 0.03 |
| Remdesivir | 0 (0.0%) | 1 (1.6%) | 0.53 | 1 (4.2%) | 0.31 |
|
| |||||
| Complications | |||||
| Sepsis | 22 (91.70%) | 29 (46.80%) | <0.001 | 22 (91.70%) | 1.00 |
| CRRT | 7 (29.20%) | 5 (8.10%) | 0.01 | 5 (20.80%) | 0.51 |
| AKI | 10 (41.70%) | 12 (19.40%) | 0.03 | 10 (41.70%) | 1.00 |
Data are expressed as mean ± standard deviation or as frequencies. A p-value <0.05 is considered statistically significant.